Abstract

PROGRAM ORGANIZATION AND CAPABILITIES 1. Scientific and Administrative Leadership This SPORE competing renewal application is submitted by the NCI-designated Vanderbilt-lngram Cancer Center (VICC). The Director of the SPORE, Carios L. Arteaga, MD, is also the Associate Director for Clinical Research and Director of the Breast Cancer Research Program at VICC. In regard to SPORE activities. Dr. Arteaga reports to Jennifer Pietenpol, PhD, Director of VICC, and has input and assistance from the Deputy Director (Daniel Beauchamp, MD) and the Associate Directors for Basic Science (Scott Hiebert, PhD) and Cancer Epidemiology, Prevention &Control (William Blot, PhD). As Director of the VICC, Dr. Pietenpol reports directly to the Vanderbilt University Medical Center (VUMC) Vice Chancellor for Health Affairs. Dr. Arteaga provides advice to Dr. Pietenpol on programmatic directions and allocation of VICC resources for clinical cancer research overall and through his leadership of the SPORE and Breast Program on breast cancer in particular. An organizational structure with key scientific interactions is included in the Figure below.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA098131-11
Application #
8595529
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (M1))
Project Start
2003-08-07
Project End
2018-08-31
Budget Start
2013-09-17
Budget End
2014-08-31
Support Year
11
Fiscal Year
2013
Total Cost
$153,607
Indirect Cost
$67,606

  Institution

Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212

  Publications

Santos Guasch, Gabriela L; Beeler, J Scott; Marshall, Clayton B et al. (2018) p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. iScience 8:236-249
Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2018) PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K? Inhibitors. Clin Cancer Res 24:1426-1435
Elion, David L; Cook, Rebecca S (2018) Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. Oncotarget 9:29007-29017
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194
Luo, Na; Nixon, Mellissa J; Gonzalez-Ericsson, Paula I et al. (2018) DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun 9:248
Sudhan, Dhivya R; Schwarz, Luis J; Guerrero-Zotano, Angel et al. (2018) Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clin Cancer Res :
Werfel, Thomas A; Wang, Shan; Jackson, Meredith A et al. (2018) Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Res 78:1845-1858
Zhao, Shilin; Li, Chung-I; Guo, Yan et al. (2018) RnaSeqSampleSize: real data based sample size estimation for RNA sequencing. BMC Bioinformatics 19:191
Jovanovi?, Bojana; Sheng, Quanhu; Seitz, Robert S et al. (2017) Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. BMC Cancer 17:241

Showing the most recent 10 out of 341 publications